T1	Participants 490 530	Male and female immunocompetent patients
T2	Participants 731 833	50% (54/109) in the imiquimod-treated group and 11% (11/100) in the vehicle-treated group ( P< 0.0001)
T3	Participants 903 936	females (72%) than in males (33%)
